IDH1 and glioblastoma: To evaluate the clinical significance of LOC in another independent cohort (Samsung Medical Center (SMC) cohort) for which we had access to patient-derived material, we used quantitative PCR (qPCR) to analyse the expression of LOC in patients with glioblastoma (n = 57) classified into the three groups—IDH-wild-type LOC high (n = 16), IDH-wild-type LOC low (n = 15) and IDH mutant (n = 8)—and noted that the patients in this cohort with high LOC expression also had significantly lower survival rates (Fig. 2l).